A transdermal drug delivery system (TTS), or transdermal patch, is a way for drugs to be absorbed into the body through the skin. TTS is a very useful form of drug delivery with many advantages. One is that when the patch is attached to the skin, drug administration can be visually confirmed. Additionally, these formulations are designed to control the rate of drug absorption, helping to maintain blood levels over a longer period of time.
The global Medical Transdermal Drug Delivery System market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Medical Transdermal Drug Delivery System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Medical Transdermal Drug Delivery System is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Medical Transdermal Drug Delivery System include 3M, Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), Johnson & Johnson, Lohmann and Teikoku Seiyaku, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Medical Transdermal Drug Delivery System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Medical Transdermal Drug Delivery System.
Report Scope
The Medical Transdermal Drug Delivery System market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Medical Transdermal Drug Delivery System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Medical Transdermal Drug Delivery System manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
3M
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Laboratoires Genevrier
Haw Par
Nichiban
Mentholatum
Segment by Type
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Others
Segment by Application
Prescription Drugs
Non-prescription Drugs
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Medical Transdermal Drug Delivery System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Medical Transdermal Drug Delivery System in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Medical Transdermal Drug Delivery System 麻豆原创 Overview
1.1 Product Overview and Scope of Medical Transdermal Drug Delivery System
1.2 Medical Transdermal Drug Delivery System Segment by Type
1.2.1 Global Medical Transdermal Drug Delivery System 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Fentanyl
1.2.3 Nitroglycerin
1.2.4 Estradiol
1.2.5 Nicotine
1.2.6 Others
1.3 Medical Transdermal Drug Delivery System Segment by Application
1.3.1 Global Medical Transdermal Drug Delivery System 麻豆原创 Value by Application: (2024-2030)
1.3.2 Prescription Drugs
1.3.3 Non-prescription Drugs
1.4 Global Medical Transdermal Drug Delivery System 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Medical Transdermal Drug Delivery System Revenue 2019-2030
1.4.2 Global Medical Transdermal Drug Delivery System Sales 2019-2030
1.4.3 Global Medical Transdermal Drug Delivery System 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Medical Transdermal Drug Delivery System 麻豆原创 Competition by Manufacturers
2.1 Global Medical Transdermal Drug Delivery System Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Medical Transdermal Drug Delivery System Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Medical Transdermal Drug Delivery System Average Price by Manufacturers (2019-2024)
2.4 Global Medical Transdermal Drug Delivery System Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Medical Transdermal Drug Delivery System, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Medical Transdermal Drug Delivery System, Product Type & Application
2.7 Medical Transdermal Drug Delivery System 麻豆原创 Competitive Situation and Trends
2.7.1 Medical Transdermal Drug Delivery System 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Medical Transdermal Drug Delivery System Players 麻豆原创 Share by Revenue
2.7.3 Global Medical Transdermal Drug Delivery System 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Medical Transdermal Drug Delivery System Retrospective 麻豆原创 Scenario by Region
3.1 Global Medical Transdermal Drug Delivery System 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Medical Transdermal Drug Delivery System Global Medical Transdermal Drug Delivery System Sales by Region: 2019-2030
3.2.1 Global Medical Transdermal Drug Delivery System Sales by Region: 2019-2024
3.2.2 Global Medical Transdermal Drug Delivery System Sales by Region: 2025-2030
3.3 Global Medical Transdermal Drug Delivery System Global Medical Transdermal Drug Delivery System Revenue by Region: 2019-2030
3.3.1 Global Medical Transdermal Drug Delivery System Revenue by Region: 2019-2024
3.3.2 Global Medical Transdermal Drug Delivery System Revenue by Region: 2025-2030
3.4 North America Medical Transdermal Drug Delivery System 麻豆原创 Facts & Figures by Country
3.4.1 North America Medical Transdermal Drug Delivery System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Medical Transdermal Drug Delivery System Sales by Country (2019-2030)
3.4.3 North America Medical Transdermal Drug Delivery System Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Medical Transdermal Drug Delivery System 麻豆原创 Facts & Figures by Country
3.5.1 Europe Medical Transdermal Drug Delivery System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Medical Transdermal Drug Delivery System Sales by Country (2019-2030)
3.5.3 Europe Medical Transdermal Drug Delivery System Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Medical Transdermal Drug Delivery System 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Medical Transdermal Drug Delivery System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Medical Transdermal Drug Delivery System Sales by Country (2019-2030)
3.6.3 Asia Pacific Medical Transdermal Drug Delivery System Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Medical Transdermal Drug Delivery System 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Medical Transdermal Drug Delivery System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Medical Transdermal Drug Delivery System Sales by Country (2019-2030)
3.7.3 Latin America Medical Transdermal Drug Delivery System Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Medical Transdermal Drug Delivery System 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Medical Transdermal Drug Delivery System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Medical Transdermal Drug Delivery System Sales by Country (2019-2030)
3.8.3 Middle East and Africa Medical Transdermal Drug Delivery System Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Medical Transdermal Drug Delivery System Sales by Type (2019-2030)
4.1.1 Global Medical Transdermal Drug Delivery System Sales by Type (2019-2024)
4.1.2 Global Medical Transdermal Drug Delivery System Sales by Type (2025-2030)
4.1.3 Global Medical Transdermal Drug Delivery System Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Medical Transdermal Drug Delivery System Revenue by Type (2019-2030)
4.2.1 Global Medical Transdermal Drug Delivery System Revenue by Type (2019-2024)
4.2.2 Global Medical Transdermal Drug Delivery System Revenue by Type (2025-2030)
4.2.3 Global Medical Transdermal Drug Delivery System Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Medical Transdermal Drug Delivery System Price by Type (2019-2030)
5 Segment by Application
5.1 Global Medical Transdermal Drug Delivery System Sales by Application (2019-2030)
5.1.1 Global Medical Transdermal Drug Delivery System Sales by Application (2019-2024)
5.1.2 Global Medical Transdermal Drug Delivery System Sales by Application (2025-2030)
5.1.3 Global Medical Transdermal Drug Delivery System Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Medical Transdermal Drug Delivery System Revenue by Application (2019-2030)
5.2.1 Global Medical Transdermal Drug Delivery System Revenue by Application (2019-2024)
5.2.2 Global Medical Transdermal Drug Delivery System Revenue by Application (2025-2030)
5.2.3 Global Medical Transdermal Drug Delivery System Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Medical Transdermal Drug Delivery System Price by Application (2019-2030)
6 Key Companies Profiled
6.1 3M
6.1.1 3M Corporation Information
6.1.2 3M Description and Business Overview
6.1.3 3M Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.1.4 3M Medical Transdermal Drug Delivery System Product Portfolio
6.1.5 3M Recent Developments/Updates
6.2 Hisamitsu
6.2.1 Hisamitsu Corporation Information
6.2.2 Hisamitsu Description and Business Overview
6.2.3 Hisamitsu Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Hisamitsu Medical Transdermal Drug Delivery System Product Portfolio
6.2.5 Hisamitsu Recent Developments/Updates
6.3 Mylan
6.3.1 Mylan Corporation Information
6.3.2 Mylan Description and Business Overview
6.3.3 Mylan Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan Medical Transdermal Drug Delivery System Product Portfolio
6.3.5 Mylan Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK Medical Transdermal Drug Delivery System Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis Medical Transdermal Drug Delivery System Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Teve (Actavis)
6.6.1 Teve (Actavis) Corporation Information
6.6.2 Teve (Actavis) Description and Business Overview
6.6.3 Teve (Actavis) Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Teve (Actavis) Medical Transdermal Drug Delivery System Product Portfolio
6.6.5 Teve (Actavis) Recent Developments/Updates
6.7 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Johnson & Johnson Medical Transdermal Drug Delivery System Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Lohmann
6.8.1 Lohmann Corporation Information
6.8.2 Lohmann Description and Business Overview
6.8.3 Lohmann Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Lohmann Medical Transdermal Drug Delivery System Product Portfolio
6.8.5 Lohmann Recent Developments/Updates
6.9 Teikoku Seiyaku
6.9.1 Teikoku Seiyaku Corporation Information
6.9.2 Teikoku Seiyaku Description and Business Overview
6.9.3 Teikoku Seiyaku Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Teikoku Seiyaku Medical Transdermal Drug Delivery System Product Portfolio
6.9.5 Teikoku Seiyaku Recent Developments/Updates
6.10 Bayer
6.10.1 Bayer Corporation Information
6.10.2 Bayer Description and Business Overview
6.10.3 Bayer Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Bayer Medical Transdermal Drug Delivery System Product Portfolio
6.10.5 Bayer Recent Developments/Updates
6.11 Lingrui
6.11.1 Lingrui Corporation Information
6.11.2 Lingrui Medical Transdermal Drug Delivery System Description and Business Overview
6.11.3 Lingrui Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Lingrui Medical Transdermal Drug Delivery System Product Portfolio
6.11.5 Lingrui Recent Developments/Updates
6.12 Sanofi
6.12.1 Sanofi Corporation Information
6.12.2 Sanofi Medical Transdermal Drug Delivery System Description and Business Overview
6.12.3 Sanofi Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Sanofi Medical Transdermal Drug Delivery System Product Portfolio
6.12.5 Sanofi Recent Developments/Updates
6.13 Qizheng
6.13.1 Qizheng Corporation Information
6.13.2 Qizheng Medical Transdermal Drug Delivery System Description and Business Overview
6.13.3 Qizheng Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Qizheng Medical Transdermal Drug Delivery System Product Portfolio
6.13.5 Qizheng Recent Developments/Updates
6.14 Endo
6.14.1 Endo Corporation Information
6.14.2 Endo Medical Transdermal Drug Delivery System Description and Business Overview
6.14.3 Endo Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Endo Medical Transdermal Drug Delivery System Product Portfolio
6.14.5 Endo Recent Developments/Updates
6.15 Laboratoires Genevrier
6.15.1 Laboratoires Genevrier Corporation Information
6.15.2 Laboratoires Genevrier Medical Transdermal Drug Delivery System Description and Business Overview
6.15.3 Laboratoires Genevrier Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Laboratoires Genevrier Medical Transdermal Drug Delivery System Product Portfolio
6.15.5 Laboratoires Genevrier Recent Developments/Updates
6.16 Haw Par
6.16.1 Haw Par Corporation Information
6.16.2 Haw Par Medical Transdermal Drug Delivery System Description and Business Overview
6.16.3 Haw Par Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Haw Par Medical Transdermal Drug Delivery System Product Portfolio
6.16.5 Haw Par Recent Developments/Updates
6.17 Nichiban
6.17.1 Nichiban Corporation Information
6.17.2 Nichiban Medical Transdermal Drug Delivery System Description and Business Overview
6.17.3 Nichiban Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Nichiban Medical Transdermal Drug Delivery System Product Portfolio
6.17.5 Nichiban Recent Developments/Updates
6.18 Mentholatum
6.18.1 Mentholatum Corporation Information
6.18.2 Mentholatum Medical Transdermal Drug Delivery System Description and Business Overview
6.18.3 Mentholatum Medical Transdermal Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Mentholatum Medical Transdermal Drug Delivery System Product Portfolio
6.18.5 Mentholatum Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Medical Transdermal Drug Delivery System Industry Chain Analysis
7.2 Medical Transdermal Drug Delivery System Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Medical Transdermal Drug Delivery System Production Mode & Process
7.4 Medical Transdermal Drug Delivery System Sales and 麻豆原创ing
7.4.1 Medical Transdermal Drug Delivery System Sales Channels
7.4.2 Medical Transdermal Drug Delivery System Distributors
7.5 Medical Transdermal Drug Delivery System Customers
8 Medical Transdermal Drug Delivery System 麻豆原创 Dynamics
8.1 Medical Transdermal Drug Delivery System Industry Trends
8.2 Medical Transdermal Drug Delivery System 麻豆原创 Drivers
8.3 Medical Transdermal Drug Delivery System 麻豆原创 Challenges
8.4 Medical Transdermal Drug Delivery System 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
3M
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Laboratoires Genevrier
Haw Par
Nichiban
Mentholatum
听
听
*If Applicable.
